Farletuzumab  (Synonyms: 法妥组单抗; MORAb-003)

Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer^[1].

Human IgG1(E356D/M358L) kappa

Human IgG1(E356D/M358L) kappa, Isotype Control

Humanized

Farletuzumab (MORAb-003; 0-10 μg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC₅₀ in a dose-dependent manner^[1].
Farletuzumab (0.1-100 μg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro^[1].
Farletuzumab (0-10 μg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

145360.00

896723-44-7

液体

Colorless to light yellow

法妥组单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Ebel W, et, al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 2007 Mar 9;7:6.  [Content Brief]